Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss.¹ It affects the retina, located at the back of the eye.

GA causes destruction of retinal cells, which are responsible for vision. Therefore, people may notice blurry spots in the center of vision, making daily activities difficult, especially in low light or dark places. GA can severely impair independence and quality of life, as it impacts essential activities like driving, reading, and recognizing faces.

We are leading the way in complement science and believe that targeting C3 has the potential to address one of the most challenging retinal diseases that patients face.

The cause of GA is thought to be multifactorial, with numerous environmental and genetic risk factors. The dysregulation of the complement cascade, an important part of the body’s immune system, plays a pivotal role.² Excessive activation of the complement cascade results in destruction of healthy cells, which can lead to the onset or progression of many diseases including GA.^3,4

We care deeply about the needs of people living with geographic atrophy. Through our scientific expertise and insights from patients and caregivers, we aim to advance care for the GA community.